Clinical trial
The Effect of AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP in Patients After Coronary Intervention Therapy
NCT07933757 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP in Patients After Coronary Intervention Therapy
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 10, 2026
- Completion date
- November 10, 2027
- Enrollment
- 250 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
coronary heart disease, inflammation
Arms
As registered; 5 arms.
-
Control group
Standard treatment for coronary heart disease
-
Colchicine group
Colchicine+standard treatment for coronary heart disease
-
Eplerenone group
Eplerenone+standard treatment for coronary heart disease
-
Leflunomide group
Leflunomide+standard treatment for coronary heart disease
-
Artesunate group
Artesunate+standard treatment for coronary heart disease
Primary endpoints
Registered primary outcome measures; 1 primary.
-
The change in hsCRP
The change in hsCRP compared to baseline
Papers
PubMed papers this trial cites; 2 papers, results papers first, then newest first.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Artesunate
- US 12121506; expires February 16, 2044; assignee Amivas Inc.
- US 12390442; expires February 16, 2044; assignee Amivas Inc.
-
Colchicine
- US 10226423; expires December 20, 2037; assignee RxOmeg Therapeutics LLC
- US 10383820; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
- US 10383821; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
- US 12274751; expires November 22, 2036; assignee RxOmeg Therapeutics LLC
- US 12514819; expires November 22, 2036; assignee not stated
- +36 more patents
-
Eplerenone
- US 4559332; expires August 11, 2007; assignee Ciba-Geigy
Lead sponsor's other trials
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, most recent start first.
+405 more trials
Similar trials
Same condition (Coronary Disease) and phase, most recent start first.
+411 more trials See the condition page